Molecular pathways: VCAM-1 as a potential therapeutic target in metastasis

Clinical Cancer Research

Volumn 18, Issue 20, 2012, Pages 5520-5525

  Chen, Qing ^a   Massagué, Joan ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA4 INTEGRIN; NATALIZUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; VASCULAR CELL ADHESION MOLECULE 1; VERY LATE ACTIVATION ANTIGEN 4;

ARTICLE; BONE MATURATION; BONE METASTASIS; BREAST CANCER; CANCER SURVIVAL; CELL MATURATION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG TARGETING; ENZYME ACTIVATION; HUMAN; LUNG METASTASIS; LYMPHOCYTIC INFILTRATION; MOLECULAR INTERACTION; MOLECULAR MODEL; MULTINUCLEAR CELL; MULTIPLE MYELOMA; MULTIPLE SCLEROSIS; NONHUMAN; OSTEOCLAST ACTIVITY; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TUMOR LOCALIZATION; TUMOR MICROENVIRONMENT;

BONE NEOPLASMS; BREAST NEOPLASMS; CELL COMMUNICATION; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; HUMANS; INTEGRIN ALPHA4BETA1; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; STROMAL CELLS; TUMOR MICROENVIRONMENT; VASCULAR CELL ADHESION MOLECULE-1;

EID: 84867494076     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-2904     Document Type: Article

References (54)

1. Fidler IJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 2003;3:453-8. (Pubitemid 37328849)
2. Nguyen DX, Bos PD, Massague J. Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 2009;9: 274-84.
3. Gupta GP, Massague J. Cancer metastasis: building a framework. Cell 2006;127:679-95. (Pubitemid 44781029)
4. Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002; 2:563-72. (Pubitemid 37328923)
5. MacDonald IC, Groom AC, Chambers AF. Cancer spread and micrometastasis development: quantitative approaches for in vivo models. Bioessays 2002;24:885-93. (Pubitemid 35180844)
6. Fidler IJ, Yano S, Zhang RD, Fujimaki T, Bucana CD. The seed and soil hypothesis: vascularisation and brain metastases. Lancet Oncol 2002;3:53-7. (Pubitemid 34121146)
7. Langley RR, Fidler IJ. The seed and soil hypothesis revisited-the role of tumor-stroma interactions in metastasis to different organs. Int J Cancer 2011;128:2527-35.
8. Chen Q, Zhang XH, Massague J. Macrophage binding to receptor VCAM-1 transmits survival signals in breast cancer cells that invade the lungs. Cancer Cell 2011;20:538-49.
9. Lu X, Mu E, Wei Y, Riethdorf S, Yang Q, Yuan M, et al. VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging alpha4beta1-positive osteoclast progenitors. Cancer Cell 2011;20:701-14.
10. Ruco LP, de Laat PA, Matteucci C, Bernasconi S, Sciacca FM, van der Kwast TH, et al. Expression of ICAM-1 and VCAM-1 in human malignant mesothelioma. J Pathol 1996;179:266-71. (Pubitemid 26266404)
11. Ding YB, Chen GY, Xia JG, Zang XW, Yang HY, Yang L. Association of VCAM-1 overexpression with oncogenesis, tumor angiogenesis and metastasis of gastric carcinoma. World J Gastroenterol 2003;9: 1409-14. (Pubitemid 36992323)
12. Shin J, Kim J, Ryu B, Chi SG, Park H. Caveolin-1 is associated with VCAM-1 dependent adhesion of gastric cancer cells to endothelial cells. Cell Physiol Biochem 2006;17:211-20. (Pubitemid 43946277)
13. Vonderheide RH, Tedder TF, Springer TA, Staunton DE. Residues within a conserved amino acid motif of domains 1 and 4 of VCAM-1 are required for binding to VLA-4. J Cell Biol 1994;125:215-22. (Pubitemid 24100051)
14. Cybulsky MI, Fries JW, Williams AJ, Sultan P, Eddy R, Byers M, et al. Gene structure, chromosomal location, and basis for alternativemRNA splicing of the human VCAM1 gene. Proc Natl Acad Sci U S A 1991;88:7859-63. (Pubitemid 21915254)
15. Luster AD, Alon R, von Andrian UH. Immune cell migration in inflammation: present and future therapeutic targets. Nat Immunol 2005; 6:1182-90. (Pubitemid 43045626)
16. Osborn L, Hession C, Tizard R, Vassallo C, Luhowskyj S, Chi-Rosso G, et al. Direct expression cloning of vascular cell adhesion molecule 1, a cytokine-induced endothelial protein that binds to lymphocytes. Cell 1989;59:1203-11. (Pubitemid 20024630)
17. Elices MJ, Osborn L, Takada Y, Crouse C, Luhowskyj S, Hemler ME, et al. VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/fibronectin binding site. Cell 1990;60:577-84.
18. Fehon RG, McClatchey AI, Bretscher A. Organizing the cell cortex: the role of ERM proteins. Nat Rev Mol Cell Biol 2010;11:276-87.
19. van Wetering S, van den Berk N, van Buul JD, Mul FP, Lommerse I, Mous R, et al. VCAM-1-mediated Rac signaling controls endothelial cell-cell contacts and leukocyte transmigration. Am J Physiol Cell Physiol 2003;285:C343-52.
20. Cardones AR, Murakami T, Hwang ST. CXCR4 enhances adhesion of B16 tumor cells to endothelial cells in vitro and in vivo via beta(1) integrin. Cancer Res 2003;63:6751-7. (Pubitemid 37322955)
21. Taichman DB, Cybulsky MI, Djaffar I, Longenecker BM, Teixido J, Rice GE, et al. Tumor cell surface alpha 4 beta 1 integrin mediates adhesion to vascular endothelium: demonstration of an interaction with the N-terminal domains of INCAM-110/VCAM-1. Cell Regul 1991;2:347-55.
22. Zhao J, Qi Q, Yang Y, Gu HY, Lu N, Liu W, et al. Inhibition of alpha(4) integrin mediated adhesion was involved in the reduction of B16-F10 melanoma cells lung colonization in C57BL/6 mice treated with gambogic acid. Eur J Pharmacol 2008;589:127-31.
23. Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, et al. Genes that mediate breast cancer metastasis to lung. Nature 2005;436: 518-24. (Pubitemid 41112921)
24. Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer 2009;9:239-52.
25. Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell 2010;141:39-51.
26. Qian B, Deng Y, Im JH, Muschel RJ, Zou Y, Li J, et al. A distinct macrophage population mediates metastatic breast cancer cell extravasation, establishment and growth. PLoS One 2009;4: e6562.
27. Qian BZ, Li J, Zhang H, Kitamura T, Zhang J, Campion LR, et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 2011;475:222-5.
28. Sterling JA, Edwards JR, Martin TJ, Mundy GR. Advances in the biology of bone metastasis: how the skeleton affects tumor behavior. Bone 2011;48:6-15.
29. Weilbaecher KN, Guise TA, McCauley LK. Cancer to bone: a fatal attraction. Nat Rev Cancer 2011;11:411-25.
30. Teitelbaum SL, Ross FP. Genetic regulation of osteoclast development and function. Nat Rev Genet 2003;4:638-49. (Pubitemid 36917505)
31. Comi G. Treatment of multiple sclerosis: role of natalizumab. Neurol Sci 2009;30 Suppl 2:S155-8.
32. Schmidt KJ, Buning J, Jankowiak C, Lehnert H, Fellermann K. Crohn's targeted therapy: myth or real goal? Curr Drug Discov Technol 2009;6:290-8.
33. Mountain A, Adair JR. Engineering antibodies for therapy. Biotechnol Genet Eng Rev 1992;10:1-142.
34. Leger OJ, Yednock TA, Tanner L, Horner HC, Hines DK, Keen S, et al. Humanization of a mouse antibody against human alpha-4 integrin: a potential therapeutic for the treatment of multiple sclerosis. Hum Antibodies 1997;8:3-16. (Pubitemid 27397156)
35. Yednock TA, Cannon C, Fritz LC, Sanchez-Madrid F, Steinman L, Karin N. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 1992;356: 63-6.
36. Lee SJ, Benveniste EN. Adhesion molecule expression and regulation on cells of the central nervous system. J Neuroimmunol 1999;98: 77-88. (Pubitemid 29317533)
37. Kent SJ, Karlik SJ, Cannon C, Hines DK, Yednock TA, Fritz LC, et al. A monoclonal antibody to alpha 4 integrin suppresses and reverses active experimental allergic encephalomyelitis. J Neuroimmunol 1995;58:1-10.
38. Hamann A, Andrew DP, Jablonski-Westrich D, Holzmann B, Butcher EC. Role of alpha 4-integrins in lymphocyte homing to mucosal tissues in vivo. J Immunol 1994;152:3282-93.
39. Hemler ME, Elices MJ, Parker C, Takada Y. Structure of the integrin VLA-4 and its cell-cell and cell-matrix adhesion functions. Immunol Rev 1990;114:45-65. (Pubitemid 20141069)
40. Elan Pharmaceuticals. A Study of ELND002 in PatientsWithRelapsing Forms of Multiple Sclerosis. In: ClinicalTrialsgov [Internet] Bethesda (MD): National Library of Medicine (US). 2011 [cited 2012 Jun 13]. Available from: http://clinicaltrials.gov/, NLM Identifier: NCT01318421.
41. Podar K, Zimmerhackl A, Fulciniti M, Tonon G, Hainz U, Tai YT, et al. The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implications. Br J Haematol 2011;155:438-48.
42. Olson DL, Burkly LC, Leone DR, Dolinski BM, Lobb RR. Anti-alpha4 integrin monoclonal antibody inhibits multiple myeloma growth in a murine model. Mol Cancer Ther 2005;4:91-9. (Pubitemid 40268070)
43. Mori Y, Shimizu N, Dallas M, Niewolna M, Story B, Williams PJ, et al. Anti-alpha4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis. Blood 2004;104: 2149-54. (Pubitemid 39297870)
44. Kibler C, Schermutzki F, Waller HD, Timpl R, Muller CA, Klein G. Adhesive interactions of human multiple myeloma cell lines with different extracellular matrix molecules. Cell Adhes Commun 1998;5: 307-23. (Pubitemid 29141887)
45. Uchiyama H, Barut BA, Chauhan D, Cannistra SA, Anderson KC. Characterization of adhesion molecules on human myeloma cell lines. Blood 1992;80:2306-14.
46. Michigami T, Shimizu N, Williams PJ, Niewolna M, Dallas SL, Mundy GR, et al. Cell-cell contact between marrow stromal cells and myeloma cells via VCAM-1 and alpha(4)beta(1)-integrin enhances production of osteoclast-stimulating activity. Blood 2000;96: 1953-60.
47. de la Fuente MT, Casanova B, Garcia-Gila M, Silva A, Garcia-Pardo A. Fibronectin interaction with alpha4beta1 integrin prevents apoptosis in B cell chronic lymphocytic leukemia: correlation with Bcl-2 and Bax. Leukemia 1999;13:266-74.
48. Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 2012;366: 1870-80.
49. Major EO. Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu Rev Med 2010; 61:35-47.
50. Miller DH, Khan OA, Sheremata WA, Blumhardt LD, Rice GP, Libonati MA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003;348:15-23. (Pubitemid 36026342)
51. Ghosh S, Goldin E, Gordon FH, Malchow HA, Rask-Madsen J, Rutgeerts P, et al. Natalizumab for active Crohn's disease. N Engl J Med 2003;348:24-32. (Pubitemid 36026343)
52. Sugiura T, Kageyama S, Andou A, Miyazawa T, Ejima C, Nakayama A, et al. A novel, orally active alpha 4 integrin antagonist, AJM300 prevents the development of experimental colitis induced by adoptive transfer of IL-10 deficient CD4+ T cells in mice. J Pharmacol Exp Ther 2012 [Epub ahead of print].
53. Takazoe M, Watanabe M, Kawaguchi T, Matumoto T, Oshitani N, Hiwatashi N, et al. Oral alpha-4 integrin inhibitor (AJM300) in patients with active Crohn's disease: a randomized, double-blind, placebocontrolled trial. Digestive Disease Week. Chicago, IL.; 2009.
54. Biogen Idec. Study of Natalizumab in Relapsed/Refractory Multiple Myeloma. In: ClinicalTrialsgov [Internet] Bethesda (MD): National Library of Medicine (US). 2008-2011. Available from: http://clinicaltrials.gov/, NLM Identifier: NCT00675428.